Gilead will present data from people treated with a liver drug for up to five years.
Gilead will present data on its liver drugs Livdelzi and Hepcludex at The Liver Meeting. The company will share late-breaking Phase 3 results from the IDEAL study on Livdelzi's impact on ALP normalization in PBC patients and long-term data on Hepcludex for HDV treatment. Gilead aims to broaden understanding of rare liver diseases and treatment outcomes.
How this was made
The 30-second read
Why it matters
The disclosed trial outcomes provide the first detailed efficacy and safety readout, potentially influencing FDA considerations and market sentiment toward Gilead's liver‑disease franchise.
Market read
New Phase 3 data for a late‑stage liver drug could be a catalyst for GILD and related biotech stocks.
What to watch
Regulatory review timelines and competition from other PBC therapies could temper upside.
Background
Gilead is showcasing late‑breaking data from its seladelpar (Livdelzi) program and long‑term real‑world evidence for Hepcludex in chronic HDV.
Ticker impact
Gilead Sciences will present new Phase 3 IDEAL trial data on seladelpar for primary biliary cholangitis at the AASLD 2026 meeting.
likely upward pressure as investors price in potential regulatory approval and market expansion.
Phase 3 results are a material catalyst for a large biotech; Gilead's size amplifies market reaction.
Market effects
Positive liver‑disease data may lift the broader biotech and hepatology therapeutic sector.
U.S. biotech stocks could see modest gains following the announcement.
International investors tracking Gilead and liver‑disease pipelines may adjust exposure.
Counterpoint
If the data show only modest ALP normalization, the market may discount the impact.
Key entities
- companyGilead Sciences
US‑listed biopharma presenting new trial data.
- eventAASLD 2026
American Association for the Study of Liver Diseases conference where data are presented.